AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 19, 2021
29864_dirs_2021-02-19_313b2a66-317f-4a2f-ab07-fec17c0a67d2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-17
Reporting Person: Sachdev Amit (EVP, Chief Patient Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-17 | Common Stock | F | 7613 | $211.75 | Disposed | 55929 | Direct |
| 2021-02-18 | Common Stock | S | 1164 | $210.00 | Disposed | 54765 | Direct |
| 2021-02-18 | Common Stock | S | 1500 | $211.36 | Disposed | 53265 | Direct |
| 2021-02-18 | Common Stock | S | 5800 | $212.15 | Disposed | 47465 | Direct |
| 2021-02-18 | Common Stock | S | 800 | $213.02 | Disposed | 46665 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 882 | Indirect |
| Common Stock | 7368 | Indirect |
Footnotes
F1: Transaction made pursuant to Mr. Sachdev's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.00 (range $209.61 to $210.34).
F3: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.36 (range $210.74 to $211.64).
F5: Open market sales reported on this line occurred at a weighted average price of $212.15 (range $211.74 to $212.70).
F6: Open market sales reported on this line occurred at a weighted average price of $213.02 (range $212.74 to $213.33).